OZAWADE市場：市場規模、予測、市場洞察-2032年

OZAWADEは、CPAPなどの一次的なOSA治療で十分な眠気が得られない成人OSA患者、またはこの治療に耐えられない患者において、覚醒度の改善とEDSの軽減を適応とします。本治療は、OSAおよび心血管リスクを専門とする医師によって開始されなければならず、OSAは毎年再評価されなければなりません。OZAWADEはOSA患者の気道閉塞の治療薬ではありません。OSAの一次治療は維持されるか、一次治療に耐えられない患者では定期的に再提案されなければなりません。

2023年1月、アキュリス製薬は、OSAを伴うEDS患者を対象としたピトリサントの第Ⅲ相臨床試験を日本で開始しました。

今後数年間で、閉塞性睡眠時無呼吸症候群（OSA）の市場シナリオは、世界中の広範な調査と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、OZAWADEの優位性に影響を与える可能性のある機会を模索しています。他のOSA治療薬もOZAWADEと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要6ヶ国における閉塞性睡眠時無呼吸症候群（OSA）治療薬のOZAWADE市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 OSAにおけるOZAWADEの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 OZAWADE市場評価

• OSAにおけるOZAWADEの市場見通し
• 主要6ヶ国分析
  • 主要6ヶ国のOSAにおけるOZAWADEの市場規模
• 国別市場分析
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: OZAWADE, Clinical Trial Description, 2023
• Table 2: OZAWADE, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: OZAWADE Market Size in the 6MM, in USD million (2019-2032)
• Table 6: OZAWADE Market Size in Germany, in USD million (2019-2032)
• Table 7: OZAWADE Market Size in France, in USD million (2019-2032)
• Table 8: OZAWADE Market Size in Italy, in USD million (2019-2032)
• Table 9: OZAWADE Market Size in Spain, in USD million (2019-2032)
• Table 10: OZAWADE Market Size in the UK, in USD million (2019-2032)
• Table 11: OZAWADE Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: OZAWADE Market Size in the 6MM, USD million (2019-2032)
• Figure 2: OZAWADE Market Size in Germany, USD million (2019-2032)
• Figure 3: OZAWADE Market Size in France, USD million (2019-2032)
• Figure 4: OZAWADE Market Size in Italy, USD million (2019-2032)
• Figure 5: OZAWADE Market Size in Spain, USD million (2019-2032)
• Figure 6: OZAWADE Market Size in the United Kingdom, USD million (2019-2032)
• Figure 7: OZAWADE Market Size in Japan, USD million (2019-2032)

"OZAWADE Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about OZAWADE for Obstructive sleep apnea (OSA) in the six major markets. A detailed picture of the OZAWADE for OSA in the 6MM, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the OZAWADE for OSA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the OZAWADE market forecast analysis for OSA in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in OSA.

Drug Summary:

OZAWADE is indicated to improve wakefulness and reduce EDS in adult patients with OSA whose sleepiness is not satisfactorily addressed by primary OSA treatment such as CPAP or those who do not tolerate this treatment. The treatment must be initiated by a physician specializing in OSA and cardiovascular risks; OSA must be re-assessed annually. OZAWADE is not a treatment for airway obstruction in patients with OSA. The primary treatment of OSA must be maintained or regularly re-proposed in patients who have not tolerated the primary treatment.

In January 2023, Aculys Pharma initiated a Phase III trial of Pitolisant treating patients with EDS associated with OSA in Japan.

Dosage

OZAWADE should be used at the lowest effective dose based on clinical response and patient tolerance. The optimal therapeutic dose must be reached in stages, without exceeding the dose of 18 mg/day:

• 1st week: an initial dosage of 4.5 mg (one tablet of 4.5 mg) per day
• 2nd week: the dosage can be increased to 9 mg (two tablets of 4.5 mg) per day
• 3rd week: the dosage can be increased to 18 mg (one tablet of 18 mg) per day or reduced to 4.5 mg (one tablet of 4.5 mg) per day.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the OZAWADE description, mechanism of action, dosage and administration, research and development activities in Obstructive sleep apnea (OSA).
• Elaborated details on OZAWADE regulatory milestones and other development activities have been provided in this report.
• The report also highlights the OZAWADE research and development activities in OSA across Europe and Japan.
• The report also covers the patents information with expiry timeline around OZAWADE.
• The report contains forecasted sales of OZAWADE for OSA till 2032.
• Comprehensive coverage of the late-stage emerging therapies for OSA.
• The report also features the SWOT analysis with analyst views for OZAWADE in OSA.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OZAWADE Analytical Perspective by DelveInsight

• In-depth OZAWADE Market Assessment

This report provides a detailed market assessment of OZAWADE for Obstructive sleep apnea (OSA) in the six major markets, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• OZAWADE Clinical Assessment

The report provides the clinical trials information of OZAWADE for OSA covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Obstructive sleep apnea (OSA) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OZAWADE dominance.
• Other emerging products for OSA are expected to give tough market competition to OZAWADE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OZAWADE in OSA.
• Our in-depth analysis of the forecasted sales data of OZAWADE from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the OZAWADE in OSA.

Key Questions:

• What is the product type, route of administration and mechanism of action of OZAWADE?
• What is the clinical trial status of the study related to OZAWADE in Obstructive sleep apnea (OSA) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OZAWADE development?
• What are the key designations that have been granted to OZAWADE for OSA?
• What is the forecasted market scenario of OZAWADE for OSA?
• What are the forecasted sales of OZAWADE in the six major countries, including Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to OZAWADE for OSA?
• Which are the late-stage emerging therapies under development for the treatment of OSA?

Table of Contents

1. Report Introduction

2. OZAWADE Overview in OSA

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. OZAWADE Market Assessment

• 5.1. Market Outlook of OZAWADE in OSA
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of OZAWADE in the 6MM for OSA
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of OZAWADE in Germany for OSA
  • 5.3.2. Market Size of OZAWADE in France for OSA
  • 5.3.3. Market Size of OZAWADE in Italy for OSA
  • 5.3.4. Market Size of OZAWADE in Spain for OSA
  • 5.3.5. Market Size of OZAWADE in the United Kingdom for OSA
  • 5.3.6. Market Size of OZAWADE in Japan for OSA

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options